EA201492067A1 - Применение связывающих семафорин-4d молекул для промотирования нейрогенеза после инсульта - Google Patents
Применение связывающих семафорин-4d молекул для промотирования нейрогенеза после инсультаInfo
- Publication number
- EA201492067A1 EA201492067A1 EA201492067A EA201492067A EA201492067A1 EA 201492067 A1 EA201492067 A1 EA 201492067A1 EA 201492067 A EA201492067 A EA 201492067A EA 201492067 A EA201492067 A EA 201492067A EA 201492067 A1 EA201492067 A1 EA 201492067A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- semaforin
- stroke
- molecules
- binding
- application
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Представлены способы промотирования нейрогенеза в нервной ткани пациента, имеющего по меньшей мере один из симптомов расстройства центральной нервной системы, включающие введение индивиду, нуждающемуся в этом, эффективного количества выделенной связывающей молекулы, которая специфически связывается с семафорином-4D (SEMA4D).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261646119P | 2012-05-11 | 2012-05-11 | |
US13/842,523 US10494440B2 (en) | 2012-05-11 | 2013-03-15 | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
PCT/US2013/040661 WO2013170221A1 (en) | 2012-05-11 | 2013-05-10 | Use of semaphorin-4d binding molecules to promote neurogenesis following stroke |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201492067A1 true EA201492067A1 (ru) | 2015-05-29 |
EA030796B1 EA030796B1 (ru) | 2018-09-28 |
Family
ID=49548777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201492067A EA030796B1 (ru) | 2012-05-11 | 2013-05-10 | Применение связывающих семафорин-4d молекул для промотирования нейрогенеза после инсульта |
Country Status (18)
Country | Link |
---|---|
US (1) | US10494440B2 (ru) |
EP (1) | EP2846831B1 (ru) |
JP (1) | JP6218810B2 (ru) |
KR (1) | KR102105436B1 (ru) |
CN (2) | CN110064054A (ru) |
AU (1) | AU2013259192B2 (ru) |
BR (1) | BR112014028160B1 (ru) |
CA (1) | CA2872928C (ru) |
DK (1) | DK2846831T3 (ru) |
EA (1) | EA030796B1 (ru) |
ES (1) | ES2882881T3 (ru) |
IL (1) | IL235603B (ru) |
MX (1) | MX358991B (ru) |
NZ (1) | NZ630864A (ru) |
PT (1) | PT2846831T (ru) |
SG (1) | SG11201407416XA (ru) |
WO (1) | WO2013170221A1 (ru) |
ZA (1) | ZA201501674B (ru) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2647823T3 (es) | 2009-05-08 | 2017-12-26 | Vaccinex, Inc. | Anticuerpos anti-CD100 y métodos de uso de los mismos |
KR101999872B1 (ko) | 2011-10-11 | 2019-07-12 | 백시넥스 인코포레이티드 | 혈뇌 장벽 투과성의 조정에 있어서의 세마포린-4d 결합 분자의 용도 |
US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
JP6611709B2 (ja) | 2013-06-25 | 2019-11-27 | バクシネックス インコーポレーティッド | 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン−4d阻害分子の使用 |
NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
DK3445397T3 (da) | 2016-04-22 | 2023-02-06 | Vaccinex Inc | Integral membrane protein display on poxvirus extracellular enveloped virions |
JP7128177B2 (ja) | 2016-08-02 | 2022-08-30 | バクシネックス インコーポレーティッド | ワクシニアウイルス/真核細胞においてポリヌクレオチドライブラリを生成するための改善された方法 |
BR112019017367A2 (pt) * | 2017-02-22 | 2020-04-14 | Vaccinex Inc | detecção precoce de ativação de célula glial em doenças neurodegenerativas ou neuroinflamatórias |
CN110636858B (zh) * | 2017-05-05 | 2024-03-19 | 瓦西尼斯公司 | 人抗脑信号蛋白4d抗体 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5070192A (en) | 1988-03-23 | 1991-12-03 | The Johns Hopkins University | Cloned human topoisomerase i: cdna expression, and use for autoantibody detection |
US5154924A (en) * | 1989-09-07 | 1992-10-13 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
DK0710719T3 (da) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Frembringelse af xenogene antistoffer |
US6497872B1 (en) | 1991-07-08 | 2002-12-24 | Neurospheres Holdings Ltd. | Neural transplantation using proliferated multipotent neural stem cells and their progeny |
FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
US5639856A (en) | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
ES2236634T3 (es) | 1997-04-07 | 2005-07-16 | Genentech, Inc. | Anticuerpos anti-vegf. |
EP0973916A1 (en) | 1997-04-11 | 2000-01-26 | Dendreon Corporation | Composition and method for inducing an immune response against tumour-related antigens |
EP0892047A3 (de) | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
US6638501B1 (en) | 1997-09-29 | 2003-10-28 | Neurospheres Holdings Ltd. | Use of multipotent neural stem cell progeny to augment non-neural tissues |
US5958767A (en) | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
CA2350207C (en) | 1998-11-10 | 2011-02-08 | University Of Rochester | T cells specific for target antigens and methods and vaccines based thereon |
JP3787473B2 (ja) | 1999-11-30 | 2006-06-21 | 独立行政法人科学技術振興機構 | セマフォリン受容体 |
US6635742B1 (en) | 2000-01-25 | 2003-10-21 | Nuvelo, Inc. | Antibodies specific for semaphorin-like polypeptides |
US7468277B2 (en) | 1999-12-23 | 2008-12-23 | Cornell Research Foundation, Inc. | Enriched preparation of human fetal multipotential neural stem cells |
WO2002102972A2 (en) | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
EP1365018A1 (en) | 2002-05-23 | 2003-11-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | CD100 semaphorin in myelination |
US7351803B2 (en) | 2002-05-30 | 2008-04-01 | Macrogenics, Inc. | CD16A binding proteins and use for the treatment of immune disorders |
EP1442749A1 (en) * | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
KR20170073698A (ko) | 2003-05-30 | 2017-06-28 | 제넨테크, 인크. | 항-vegf 항체를 사용한 치료 |
WO2005058965A1 (en) | 2003-12-11 | 2005-06-30 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
CA2554735A1 (en) * | 2004-01-30 | 2005-08-11 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
JP2008504821A (ja) * | 2004-07-01 | 2008-02-21 | バイレクシス コーポレイション | ベクター・パッケージング細胞系列 |
PT1773885E (pt) | 2004-08-05 | 2010-07-21 | Genentech Inc | Antagonistas anti-cmet humanizados |
US20060147449A1 (en) | 2004-11-15 | 2006-07-06 | Brass Lawrence F | Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses |
AU2006235271B2 (en) | 2005-04-07 | 2011-05-19 | Novartis Vaccines And Diagnostics Inc. | SEMA4D in cancer diagnosis, detection and treatment |
JP2007308465A (ja) | 2006-05-15 | 2007-11-29 | Boehringer Ingelheim Internatl Gmbh | 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法 |
ATE494306T1 (de) | 2007-02-14 | 2011-01-15 | Vaccinex Inc | Humanisierte anti-cd100-antikörper |
US20090181035A1 (en) | 2008-01-10 | 2009-07-16 | Genentech, Inc. | Plexind1 agonists and their use |
CN102421913A (zh) * | 2009-03-13 | 2012-04-18 | 宾夕法尼亚大学董事会 | Ox40/trail融合蛋白 |
ES2647823T3 (es) | 2009-05-08 | 2017-12-26 | Vaccinex, Inc. | Anticuerpos anti-CD100 y métodos de uso de los mismos |
ES2679043T3 (es) | 2009-05-15 | 2018-08-21 | Irx Therapeutics, Inc. | Inmunoterapia de vacuna |
WO2011159704A1 (en) | 2010-06-14 | 2011-12-22 | Vaccinex, Inc. | Anti-vegf antibodies and uses thereof |
ES2640567T3 (es) | 2011-05-13 | 2017-11-03 | National University Corporation Tokyo Medical And Dental University | Promotor de la osteogénesis |
KR101999872B1 (ko) | 2011-10-11 | 2019-07-12 | 백시넥스 인코포레이티드 | 혈뇌 장벽 투과성의 조정에 있어서의 세마포린-4d 결합 분자의 용도 |
US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
JP6611709B2 (ja) | 2013-06-25 | 2019-11-27 | バクシネックス インコーポレーティッド | 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン−4d阻害分子の使用 |
NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
BR112019017367A2 (pt) * | 2017-02-22 | 2020-04-14 | Vaccinex Inc | detecção precoce de ativação de célula glial em doenças neurodegenerativas ou neuroinflamatórias |
-
2013
- 2013-03-15 US US13/842,523 patent/US10494440B2/en active Active
- 2013-05-10 DK DK13787931.8T patent/DK2846831T3/da active
- 2013-05-10 KR KR1020147034510A patent/KR102105436B1/ko active IP Right Grant
- 2013-05-10 WO PCT/US2013/040661 patent/WO2013170221A1/en active Application Filing
- 2013-05-10 EP EP13787931.8A patent/EP2846831B1/en active Active
- 2013-05-10 CN CN201910064594.5A patent/CN110064054A/zh active Pending
- 2013-05-10 CN CN201380037262.9A patent/CN104619341A/zh active Pending
- 2013-05-10 EA EA201492067A patent/EA030796B1/ru not_active IP Right Cessation
- 2013-05-10 AU AU2013259192A patent/AU2013259192B2/en active Active
- 2013-05-10 MX MX2014013676A patent/MX358991B/es active IP Right Grant
- 2013-05-10 CA CA2872928A patent/CA2872928C/en active Active
- 2013-05-10 PT PT137879318T patent/PT2846831T/pt unknown
- 2013-05-10 BR BR112014028160-2A patent/BR112014028160B1/pt active IP Right Grant
- 2013-05-10 NZ NZ630864A patent/NZ630864A/en unknown
- 2013-05-10 SG SG11201407416XA patent/SG11201407416XA/en unknown
- 2013-05-10 JP JP2015511789A patent/JP6218810B2/ja active Active
- 2013-05-10 ES ES13787931T patent/ES2882881T3/es active Active
-
2014
- 2014-11-10 IL IL235603A patent/IL235603B/en active IP Right Grant
-
2015
- 2015-03-11 ZA ZA2015/01674A patent/ZA201501674B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20130302320A1 (en) | 2013-11-14 |
KR20150018555A (ko) | 2015-02-23 |
IL235603B (en) | 2020-01-30 |
DK2846831T3 (en) | 2021-10-11 |
ES2882881T3 (es) | 2021-12-03 |
BR112014028160B1 (pt) | 2021-01-12 |
NZ630864A (en) | 2017-03-31 |
ZA201501674B (en) | 2021-06-30 |
EA030796B1 (ru) | 2018-09-28 |
MX358991B (es) | 2018-08-31 |
EP2846831B1 (en) | 2021-07-07 |
PT2846831T (pt) | 2021-08-19 |
EP2846831A4 (en) | 2015-11-18 |
AU2013259192B2 (en) | 2018-02-22 |
CN110064054A (zh) | 2019-07-30 |
IL235603A0 (en) | 2015-01-29 |
SG11201407416XA (en) | 2015-03-30 |
JP6218810B2 (ja) | 2017-10-25 |
CA2872928C (en) | 2021-02-16 |
JP2015517502A (ja) | 2015-06-22 |
EP2846831A1 (en) | 2015-03-18 |
KR102105436B1 (ko) | 2020-04-29 |
CA2872928A1 (en) | 2013-11-14 |
US10494440B2 (en) | 2019-12-03 |
AU2013259192A1 (en) | 2014-11-27 |
MX2014013676A (es) | 2015-02-05 |
WO2013170221A1 (en) | 2013-11-14 |
CN104619341A (zh) | 2015-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201492067A1 (ru) | Применение связывающих семафорин-4d молекул для промотирования нейрогенеза после инсульта | |
CY1122278T1 (el) | Αντι il-36r αντισωματα | |
CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
CY1121203T1 (el) | Θεραπευτικες χρησεις της εμπαγλιφλοζινης | |
PH12014501702A1 (en) | Imidazopyrrolidinone compounds | |
MX353550B (es) | Uso de moleculas de enlace a semaforina-4d para la modulacion de la permeabilidad de la barrera sangre-cerebro. | |
EA201391585A1 (ru) | Терапевтические нуклеазные композиции и способы | |
BR112014008294A2 (pt) | anticorpo anti c-met e usos do mesmo | |
EA201490420A1 (ru) | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С α-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ | |
EA201890915A1 (ru) | Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma | |
AU2012205878A8 (en) | miRNA for treating diseases and conditions associated with neo-angiogenesis | |
EA201401204A1 (ru) | Антитела к il-23p19 | |
ECSP14001249A (es) | Inmunoenlazadores dirigidos contra el tnf | |
UA115122C2 (uk) | Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським | |
UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
EA202090031A3 (ru) | Человеческие антитела против gfr3 и способы их применения | |
EA201690728A1 (ru) | Применение молекул, связывающих семафорин-4d, для лечения атеросклероза | |
EA201301107A1 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
EA201591843A1 (ru) | Способы лечения несовершенного остеогенеза | |
BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
EA201500370A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИОПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF-R АГЕНТЫ | |
TR201907907T4 (tr) | Benralizumab kullanarak astımlı hastalarda zorlu ekspiratuar hacmi arttırma yöntemleri. | |
TR201910413T4 (tr) | Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler. | |
EA201590782A1 (ru) | Оксирановые амины | |
CY1117740T1 (el) | Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |